EUVIMEDEUVIMED entdecken
Crossref

Developing New Pyrido[2,3-d]pyrimidine-Based Small Molecules as Potent ATR Inhibitors

Faraz Ghous, Sivapriya Kirubakaran

Synlett · 01.01.2026 · 37 (01) · 108-116

DOI: 10.1055/a-2705-9462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Synlett, erschienen am 01.01.2026. Verfasst von Faraz Ghous und 1 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ataxia Telangiectasia and Rad3-related (ATR), a key enzyme of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, that plays a vital role in controlling the DNA damage response (DDR). ATR has become more essential for the survival of tumour cells that have deficiencies in the ataxia telangiectasia mutated (ATM) gene or a lack of DDR function. This indicates that ATR is an important target for anticancer drugs due to its synthetic lethality. In this article, we present a potent and highly selective pyrido[2,3-d]pyrimidine based novel ATR inhibitor. All the synthesized compounds were characterized by using 1H NMR, 13C NMR, and HRMS analysis, and they were all produced in good to excellent yields. In silico studies were conducted on a synthesized compound (4a) using density functional theory (DFT) at B3LYP/6-311++G(d,p) level. Results showed good predictions for pharmacokinetics, medicinal properties, physicochemical, and lipophilicity. ADMET studies predicted target molecule properties and simulated molecular docking between ligand and receptors.

Zitieren

APA

Ghous, F., & Kirubakaran, S. (2026). Developing New Pyrido[2,3-d]pyrimidine-Based Small Molecules as Potent ATR Inhibitors. Synlett, 37(01), 108-116. https://doi.org/10.1055/a-2705-9462

Vancouver

Ghous F, Kirubakaran S. Developing New Pyrido[2,3-d]pyrimidine-Based Small Molecules as Potent ATR Inhibitors. Synlett. 2026;37(01):108-116. doi:10.1055/a-2705-9462

BibTeX
@article{Ghous2026,
  author = {Ghous, Faraz and Kirubakaran, Sivapriya},
  title = {Developing New Pyrido[2,3-d]pyrimidine-Based Small Molecules as Potent ATR Inhibitors},
  journal = {Synlett},
  year = {2026},
  volume = {37},
  number = {01},
  pages = {108--116},
  doi = {10.1055/a-2705-9462}
}
Kostenlos starten →